Low B12 and Cardiovascular Risk: What the Review Shows

A low B12 measurement can be associated with cardiovascular risk in observational research. That association does not establish that taking B12 supplements prevents heart attacks. The October 26, 2026 Nutrition Journal review discusses this difference.

What kind of evidence is it?

The paper is a review combining mechanistic, observational and intervention research, rather than a newly reported prevention trial. The publisher labels the reviewed version as an accepted early article that may receive further edits. Sources checked October 31, 2026.

Finding	What it does not establish
Low B12 is associated with adverse outcomes	B12 deficiency caused every observed event
Supplements can lower homocysteine	Lowering that marker guarantees fewer clinical events
Some trials suggest benefits in particular settings	The same benefit applies to everyone

The review reports mixed cardiovascular-event outcomes and emphasizes differences between populations. It discusses functional markers such as methylmalonic acid, while noting limits in predicting cardiovascular endpoints. These statements summarize the paper; Varwo has not reanalysed its underlying studies.

Compare with clinical reference information

The NIH Office of Dietary Supplements fact sheet similarly distinguishes homocysteine biology from evidence about cardiovascular prevention. Treating an established deficiency and taking a supplement solely to prevent cardiovascular disease are different questions.

This article explains research and cannot diagnose a low result, calculate your personal cardiovascular risk or select a supplement dose. If you have a low measurement or symptoms, discuss the result, possible causes and an appropriate plan with a qualified clinician. Do not change prescribed treatment on the basis of a search headline.

For another example of evaluating a scientific claim's scope, see AI and theoretical computer science.